OcuLearning › Neuro

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

URGENT — Neuro

Symptoms

Sudden, painless, unilateral vision loss (often noticed upon awakening)
Typical age 50–70 years (younger if strong vasculopathic risk factors are present)
Altitudinal visual field defect (typically inferior)
Absence of pain on eye movement

Clinical Findings

Clinical Exam

Relative Afferent Pupillary Defect (RAPD) — essentially always present in unilateral cases
Variable visual acuity (ranging from 20/20 to count fingers; often >20/64)
Dyschromatopsia proportional to the degree of visual acuity loss

Funduscopy

Segmental or diffuse pallid (pale) optic disc swelling
Flame hemorrhages at or near the disc margin
Fellow eye: small, crowded optic nerve head ("disc at risk" with a C/D ratio ≤0.2)

Evolution

Disc edema typically resolves to optic atrophy without cupping within 4–8 weeks
Stable visual field/acuity after the initial event; spontaneous mild improvement occurs in ~30%

Etiology

Pathophysiology

Acute ischemia of the short posterior ciliary arteries (SPCAs) supplying the anterior optic nerve
Anatomic compartment syndrome: axonal swelling inside a tight, crowded scleral canal ("disc at risk")

Risk Factors

Vasculopathic: hypertension (especially nocturnal dips), diabetes mellitus, hyperlipidemia
Sleep apnea: strong correlation (routinely screen with the STOP-BANG questionnaire)
Systemic: anemia, perioperative hypotension (e.g., prolonged prone spine or cardiac surgeries)
Medications: PDE-5 inhibitors (sildenafil, tadalafil), amiodarone

Red Flags

ALWAYS exclude Arteritic AION / Giant Cell Arteritis (GCA): check for age ≥70, chalky-white edema, jaw claudication, scalp tenderness, or systemic symptoms
Progression beyond 2–4 weeks: strongly consider a compressive or infiltrative optic neuropathy
Fellow-eye involvement: occurs in roughly 15–25% of patients within 5 years

Investigations

Urgent Labs (To Rule Out GCA)

Same-day ESR, CRP, and complete blood count (for platelet count) for all patients aged ≥50

Ophthalmic Testing

Automated perimetry (Visual Field): documents an altitudinal defect or a horizontal step
Fundus photography and OCT RNFL: used to baseline and document active edema vs. subsequent atrophy

Systemic Workup

Blood pressure monitoring (assess for nocturnal troughs), HbA1c, and lipid panel
Polysomnography (sleep study) if Obstructive Sleep Apnea (OSA) is suspected
MRI of the brains and orbits: indicated only if presentation is atypical (pain, progression, or young age)

Treatment

Acute Management

No proven effective treatment exists (systemic steroids and surgical optic nerve decompression are not standard of care)
Antiplatelet or anticoagulant therapies show no proven benefit for the acute event

Risk Modification

Avoid nocturnal hypotension: advise moving evening anti-hypertensive medications to the morning layout
Treat obstructive sleep apnea aggressively with CPAP therapy if diagnosed
Discontinue PDE-5 inhibitors immediately if a temporal association is suspected
Optimize systemic factors: glycemic index, lipid profiles, and smoking cessation

Clinical Pearl

NAION: "Disc at risk" — a structurally small cup-to-disc ratio leaves no baseline geographic room for nerve fibers to swell without secondary mechanical compression. Nocturnal hypotension (trough blood pressure) acts as a classic trigger; taking anti-hypertensives right at bedtime can exacerbate this drop. The 5-year recurrence risk in the fellow eye hovers around 15–25%, whereas recurrence in the exact same eye is incredibly rare. PDE-5 inhibitors are strongly linked to incidents, particularly in patients holding the classic structural disc at risk.

Differential Diagnosis

• Arteritic Anterior Ischemic Optic Neuropathy (AAION / Giant Cell Arteritis)
• Optic Neuritis (demyelinating or atypical atypical presentations)
• Compressive or Infiltrative Optic Neuropathy
• Papilledema (bilateral early on, but can present asymmetrically)
• Diabetic Papillopathy